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Background: Cowpox virus expresses the serpin CrmA (cytokine response
modifier A) in order to avoid inflammatory and apoptotic responses of infected
host cells. The targets of CrmA are members of the caspase family of proteases
that either initiate the extrinsic pathway of apoptosis (caspases 8 and 10) or
trigger activation of the pro-inflammatory cytokines interleukin-1β and
interleukin-18 (caspase 1). 
Results: We have determined the structure of a cleaved form of CrmA to
2.26 Å resolution. CrmA has the typical fold of a cleaved serpin, even though
it lacks the N-terminal half of the A helix, the entire D helix, and a portion of
the E helix that are present in all other known serpins. The reactive-site loop
of CrmA was mutated to contain the optimal substrate recognition sequence
for caspase 3; however, the mutation only marginally increased the ability of
CrmA to inhibit caspase 3. Superposition of the reactive-site loop of α1-
proteinase inhibitor on the cleaved CrmA structure provides a model for
virgin CrmA that can be docked to caspase 1, but not to caspase 3. 
Conclusions: CrmA exemplifies viral economy, selective pressure having
resulted in a ‘minimal’ serpin that lacks the regions not needed for structural
integrity or inhibitory activity. The docking model provides an explanation for the
selectivity of CrmA. Our demonstration that engineering optimal substrate
recognition sequences into the CrmA reactive-site loop fails to generate a good
caspase 3 inhibitor is consistent with the docking model.
Introduction
Animal development and homeostasis both depend on
the ability of cells to die in an orderly fashion, by a
process known as apoptosis. Apoptosis requires the par-
ticipation of several members of a protease family known
as the caspases [1,2]. Because animals remove viruses by
inducing apoptosis in infected cells, viruses have
evolved countermeasures that attempt to defeat the
host’s apoptotic response. One of the best known coun-
termeasures is the caspase inhibitor known as cytokine
response modifier A (CrmA) [3]. CrmA targets the apical
caspase of the extrinsic apoptotic pathway (caspase 8),
protecting the virus against apoptosis triggered by death
receptor engagement [4,5]. CrmA also targets the pro-
inflammatory cytokine activator (caspase 1), helping to
prevent inflammatory signal transmission from infected
cells [6,7]. The benefit to cowpoxvirus afforded by
CrmA is substantial, as viruses devoid of the gene are
drastically attenuated in infectivity and virulence [3,8].
On the basis of sequence conservation CrmA is classified 
as a member of the serpin family, which contains seve-
ral protease inhibitors that target essential coagulation
and fibrinolytic serine proteases [9]. CrmA differs from
other serpins in that it is able to efficiently inhibit both
cysteine proteases (caspases) and serine proteases
(granzyme B and Streptomyces griseus protease E) that
accept aspartate sidechains in their S1 pockets [10,11].
CrmA is thus a cross-class inhibitor, and illustrates the
adaptability of serpins in their inhibition of proteases
that utilize serine and cysteine catalytic nucleophiles;
this property is not found in other active-site-directed
protease inhibitor families [12].
In addition to its cross-class inhibitory property, CrmA is
also a ‘minimal’ serpin. An alignment of CrmA with all
other known serpins shows that it apparently lacks half
of the A helix and the entire D helix, both of which are
otherwise highly conserved throughout the serpin family
and contain important regulatory sites. As discussed
elsewhere [13], the serpin architecture seems to tolerate
only a limited range of changes, so that serpins evolve
against a strong selective pressure. As the serpin fold has
been described by various authors [14], we will focus
here primarily on the description of structural differ-
ences between CrmA and other serpins, and attempt to
understand the  inhibitory specificity of CrmA for indi-
vidual caspases. 
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Results and discussion
The CrmA structure
CrmA was expressed in Escherichia coli, purified, and
treated with a catalytic amount of subtilisin Carlsberg,
resulting in a cleavage of the peptide bond between Ala359
and Ser360 (sequence numbering throughout this paper is
based on the topological similarity with α1-proteinase
inhibitor). Cleaved CrmA crystallized in two different
crystal forms (orthorhombic primitive, P212121, and
orthorhombic centered, C2221). The structure was solved
in both crystal forms and refined to an R factor of 23.2%
(Rfree of 27.7%) using the higher resolution data set (2.26 Å;
P212121). The structure of the lower resolution data set
(2.5 Å; C2221) could only be refined to an R factor of 29.8%
(Rfree of 35%) as the crystals turned out to have a significant
level of merohedral twinning. A detailed summary of data
collection and refinement statistics is given in Table 1.
The structure of CrmA shows the typical fold of a cleaved
serpin (Figure 1), as first described for α1-proteinase
inhibitor [15] and now observed in a variety of other
structures including cleaved α1-antichymotrypsin [16],
antithrombin [17,18], and leukocyte elastase inhibitor
[19]. CrmA is an ellipsoidal molecule with dimensions 70
Å × 45 Å × 50 Å. Eighty percent of the amino acid
residues are involved in three β sheets and eight α helices
connected by mostly short loops and turns, forming a
single  large structural domain (Figure 1). In the final
model most of the mainchain and sidechain atoms are
defined by the electron density. Exceptions are the
amino acids between residues 80 and 100 (see below) and
some of the N-terminal and C-terminal residues. The
structure from both crystal forms is virtually identical.
The only differences are seen C-terminal to the cleavage
site, from residue Ser360 to Asn363A (see below).
Despite its low sequence identity with other serpins, its
unusual specificity and its ability to inhibit both serine and
cysteine proteases, the overall structure of CrmA shows
almost complete structural identity to serpins originating
from other organisms. Optimal superposition of CrmA (341
residues) with human α1-antitrypsin (394 residues; Protein
Data Bank [PDB] accession code 7API [15]) and horse
leukocyte elastase inhibitor (379 residues; PDB code
1HLE [19]), using a distance cutoff of 1.5 Å, identifies 209
and 212 equivalent Cα positions, respectively; the respec-
tive root mean square deviations (rmsds) are 0.82 Å and
0.70 Å. The best fit obtained for the superimposition of
CrmA with 7API and 1HLE is in the region of the three
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Figure 1
Ribbon diagram of cleaved CrmA. Secondary structure elements that
are referred to in the text are named according to the nomenclature of
Huber and Carrel [14]. The central β sheet A is colored in green, sheet
B in blue, and sheet C in red. The figure was generated using the
programs MOLSCRIPT [46] and Raster3D [47].
Table 1
Crystallographic data and refinement.
Data set
Space group C2221 P212121
Temperature (K) 298 100
Cell constants (Å)
a,b,c 87.3, 136.3, 87.0 49.2, 92.5, 100.5
No. measurements 17,913 22,001
Completeness (%)
overall/outermost shell 96.8/86.9* 98.7/94.5†
Rmerge(%)
overall/outermost shell 5.2/33.6* 5.0/28.6†
Number of atoms/asymmetric unit
nonhydrogen protein atoms 2607 2607
solvent molecules 0 168 including 1DTT‡
Resolution range (Å) 50–2.5 50–2.26
No. reflections 
in refinement 17,693 21,293
to calculate Rfree 1746 2100
Completeness (2σ cutoff) (%) 96.6 96.2
R/Rfree (%) 30.7/35.3 22.77/27.2
Root mean square deviation
bond lengths (Å) 0.009 0.015
bond angles (°) 1.36 1.72
mainchain/sidechain (Å) 1.18/1.56 1.31/1.66
*Outermost shell 2.53–2.49 Å; †outermost shell 2.33–2.26 Å. ‡The
DTT molecule is in its reduced form; it interacts with Cys389.
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β sheets; the strongest deviations are seen in the helices on
the back side of the molecule (Figure 2).
A structure-based sequence alignment of CrmA with human
α1-proteinase inhibitor, human antithrombin, horse leuko-
cyte elastase inhibitor and chicken ovalbumin shown in
Figure 3. Residues are numbered on the basis of the super-
position with α1-proteinase inhibitor, the archetype of the
superfamily. This numbering system is used in all the paper.
CrmA as the minimal serpin
Compared with the α1-proteinase inhibitor and other
known serpin structures, CrmA has three prominent
deletions (Figures 2 and 3). These deletions are found
on the ‘east’ side of the molecule (orientation as in
Figure 1) and comprise the beginning of helix A, the
entire helix D and the end of Helix E. Helix A is only
half the normal length, and the distal end superim
poses well with other known serpin structures. The N-
terminal residue Met36 is not accessible to solvent. The
sidechain of this residue is buried in a hydrophobic
groove formed by the residues Leu267, Phe272, Val373,
Ile382 and Val385. The electron density shows no 
indication of an N-terminal modifications; the N-termi-
nal amino group forms a salt bridge to the sidechain 
of Asp269.
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Figure 2
Superimposition of CrmA with human
α1-proteinase inhibitor. CrmA is shown in blue
and α1-proteinase inhibitor (PDB code 1PSI)
is in gray. For clarity, the N-terminal residues
Cys8 to Ser25 (numbering as in PDB file
1PSI, in α1-proteinase inhibitor residues –17
to –1) are not shown. Every tenth Cα atom in
CrmA is highlighted. Three regions of the α1-
proteinase inhibitor (half of the A helix, the
entire D helix and parts of the E helix) are
highlighted in orange. These regions are not
present in CrmA and are the most prominent
deletions in CrmA when compared with other
members of the serpin family. The residues
between Lys82 and Phe112 of CrmA are
topologically equivalent to the D helix of α1-
proteinase inhibitor. As these residues are
undefined by electron density in the present
structure, residues Lys82 and Phe112 are
shown connected by a dotted line.
(a) Stereoview Cα trace oriented as in
Figure 1. (b) The molecule is rotated 180°
around a vertical axis with respect to Figure 1.
The figure was generated using the programs
MOLSCRIPT [46] and Raster3D [47].
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In both crystal forms no interpretable electron density
could be found for residues Lys82 to Phe112, correspond-
ing to 12 consecutive amino acids of the primary
sequence (see Figure 3). Sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS–PAGE) analysis of
the crystals shows no indication of any cleavage in this
segment. Weak electron density for residues Glu83 to
Asp85 shows no indication for a helical conformation, but
instead suggests an extended conformation. The five
residues from Lys105 to Asp109 show no electron density,
and the gap is of a size consistent with a short loop.
Adjacent to the D loop of CrmA is a four amino acid dele-
tion (residues 137–140 in α1-proteinase inhibitor) at the
end of helix E and in turn hEs1A. Interestingly, this
includes the deletion of a tyrosine residue that is highly
conserved in the serpin family (Tyr138 in α1-proteinase
inhibitor) [14]. In α1-proteinase inhibitor and horse leuko-
cyte elastase inhibitor, Tyr138 Oε hydrogen bonds to
His93 Nδ of helix D and clusters with Met63, Leu66 and
Phe82, all residues that are highly conserved among the
serpins but mutated in CrmA. The probable function of
these interactions is to stabilize the conformation of
helix D. With the deletion of helix D in CrmA the selec-
tive pressure to conserve the residues at positions 63, 66,
82 and the segment of residues 137–140 is lost.
The D helix is known to be a regulatory site in other
serpins. For example, the D helix of antithrombin and
heparin cofactor 2 contain heparin-binding elements that
792 Structure 2000, Vol 8 No 7
Figure 3
Structure-based sequence alignment. The
alignment includes CrmA from cowpox
(CRMA_COWPX) human α1-proteinase
inhibitor (PDB code 7API; A1AT_HUMAN),
human antithrombin (PDB code 7API
ANT3_HUMAN), horse leukocyte elastase
inhibitor (PDB code 1HLE; ILEU_HORSE)
and chicken ovalbumin (PDB code 1OVA;
OVAL_CHICK). The alignment was generated
using the program ALSCRIPT [48]. Gray
boxes identify residues identical in at least
three of the five sequences. The black boxes
identify the P1 residues; note that the P1
residue in CrmA is shifted by one residue
relative to all other shown serpins. The
consensus sequence is the Munich
Information Centre for Protein Sequences
serpin family (family 00998) consensus from
the appropriate database
(http://www.mips.biochem.mpg.de.)
Secondary structure elements are colored as
shown in Figure 1 and named following the
nomenclature of Huber and Carell [14].
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activate these serpins for inhibition of their target pro-
teases [20,21]. Furthermore, the antiapoptotic function
of plasminogen activator inhibitor 2 requires sequences
adjacent to the D helix [22] and the nuclear translocation
signal in bomabin is located in the D helix [23]. We con-
clude that this regulatory patch has been abolished in
CrmA, and surmise that CrmA is not a cofactor-regulated
serpin. Interestingly, the linker sequence that replaces
the D helix is the most variable region in CrmA
homologs from other pox viruses, such as vaccinia, small-
pox and cowpox viruses, which are otherwise more than
90% identical.
The reactive-site loop
For this study the reactive-site loop (RSL) was cleaved
with a catalytic amount of the protease subtilisin Carls-
berg, between the residues Ala359 and Ser360 (P2′–P3′).
This cleavage site is two residues upstream of the physio-
logical cleavage site Asp357–Cys358 (P1–P1′). As seen in
the structures of several other serpins, CrmA adopts the
so-called ‘relaxed’ conformation with the two residues
flanking the cleavage site separated by 70 Å. The
upstream segment from residue Tyr344 to Ala359
(P15–P2′) becomes inserted into β sheet A forming its
central strand s4A. This observation demonstrates that
CrmA can utilize the classic RSL-insertion mechanism in
spite of being a minimal serpin.
In contrast to the upstream segment of the RSL, the
downstream segment, Ser360 to Asn363A (P3′–P7′), only
makes a few interactions with the rest of the molecule and
is therefore rather flexible. In the orthorhombic primitive
(P212121) crystal form this segment runs roughly antiparal-
lel to strand s1B forming hydrogen bonds. The carbonyl
oxygen atoms of Ser360 and Val362 are hydrogen bonded
to Lys233 Nζ and Ser231 Oγ, respectively. In the twinned
crystal form (C2221) residues Ser360 to Glu363B are in an
extended conformation. They contact residues 213–216
(strand s3C) of a symmetry-related molecule in a β-sheet-
like interaction, yet there is no indication of oligomeriza-
tion that is sometimes seen in RSL-cleaved serpins (see
the crystal structures of α1-anti-trypsin with PDB codes
1QMB and 1D5S).
Unusual features of the RSL
The protease inhibitory mechanism of serpins is thought
to require, at an early stage, the insertion into the central β
sheet A of several residues in the segment surrounding
residue 345 [24–27]. This segment, called the ‘hinge
region’, appears to be unusual in CrmA. All known serpins
(there are more than 100 sequences in the Protein families
database of alignments and HMMS database;
http://www.sanger.ac.uk/Pfam) contain a glycine at posi-
tion 344, with just two exceptions — CrmA and the
related orthopoxvirus serpin B24R (also known as Spi1).
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Figure 4
Stereoview of the electron density. Parts of
the central β sheet A (strands 3A, 4A, 5A and
6A, right to left, and turn s5As4A) are
superimposed with the final 2Fo–Fc electron-
density map contoured at 0.8σ. The atoms are
colored by type: blue, carbon; cyan, nitrogen;
and red, oxygen. The figure was made with
the program BobScript [49].
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Both serpins possess a tyrosine at this position, and in the
structure of cleaved CrmA Tyr344 is the fourth residue in
the α turn s5As4A. The sidechain of Tyr344 points from
the molecular surface into the solvent without making any
unusual contacts. This residue is well defined by electron
density (see Figure 4), and the temperature factors do not
suggest any higher mobility. The φ,ψ angles of Tyr344 lie
in the allowed region of the Ramachandran plot.
Evidently, Tyr344 does not hamper the conformation of
the cleaved CrmA. But might it influence the conforma-
tion of the RSL in the uncleaved (inhibitory) conforma-
tion? We modeled the substitution of tyrosine for the
consensus Gly344 in the known structures of uncleaved,
resting serpins. In all cases, this required only minor
changes of some sidechain torsion angles. Consequently
we assume that Tyr344 does not influence the resting,
inhibitory conformation of CrmA and that this conforma-
tion would be similar to that of other serpins.
To test the importance of Tyr344 we cloned, expressed
and purified a CrmA mutant with a glycine residue at this
position (Tyr344→Gly). The rate of inhibition and stabil-
ity of the resulting complex of caspase 8 with the mutant
CrmA (kon 3.6 × 105 M–1 s–1) showed no difference to wild-
type (kon 3.5 × 105 M–1 s–1), and there is no sign of an
altered partition ratio for the mutant (data not shown).
The partition ratio defines the number of inhibitor mol-
ecules needed for complete inhibition of the target pro-
tease, and is heavily influenced by mutations in the RSL
of other serpins [28]. The only difference we could ascribe
to the Tyr344Gly mutant was a slight but con
sistent increase in stability at elevated temperature 
(t1/2, 46°C = 200 min) compared with wild-type CrmA 
(t1/2, 46°C = 120 min). Therefore, on the basis of our
in vitro observations, we conclude that Tyr344 would not
influence the inhibitory mechanism of CrmA under
normal conditions expected during viral infection in vivo.
Specificity for caspases
CrmA does not inhibit all caspases with the same efficiency.
It is a strong inhibitor of caspases 1 and 8, but a much
weaker inhibitor of caspase 3 [4]. In order to understand the
selectivity of CrmA for caspase 1 over caspase 3 we con-
structed a mutant with an altered RSL sequence, the idea
being to increase the selectivity of CrmA for caspase 3.
Positional scanning to determine the P4–P2 subsite prefer-
ences of caspases [29] showed that the sequence Leu-Val-
Ala (P4–P2 in wild-type CrmA) is not optimal for
recognition by caspase 3. Therefore, we changed P4–P2
into Asp-Glu-Val, the preferred caspase 3 substrate
sequence, on the grounds that presenting an optimal sub-
strate sequence should provide increased inhibitory power.
As expected, the inhibition rate against caspases 1 and 8
dropped dramatically (kon decreased by two to three orders
of magnitude). In addition, a moderate increase in caspase 3
inhibition was achieved (kon increased from 1.6 × 102
M–1 s–1 for the wild type to 1.4 × 103 M–1 s–1 for the mutant).
These results confirm the importance of the RSL sequence
in determining the affinity of CrmA for caspases 1 and 8.
However, the mutant is still a poor inhibitor of caspase 3,
even though it now contains an optimal substrate-binding
sequence. A similar failure to direct the specificity of CrmA
towards caspase 3 based on comparable mutants has been
identified previously [30]. Together, these results indicate
that additional interactions distinct from those in the sub-
strate cleft allow good inhibition of caspases 1 and 8, but
prevent potent inhibition of caspase 3.
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Figure 5
Stereoview docking model of CrmA with
caspases 1 and 3. The upper molecules show
the equivalent substrate-binding regions of
caspase 1 in gray and caspase 3 in red. The
intact reactive-site loop in cyan is modeled
onto the CrmA structure in blue using the
structure of active α1-proteinase inhibitor
(1PSI). Surface loops of caspase 3 that differ
from caspase 1 are highlighted in red. The
most prominent difference between
caspases 3 and 1 is the 381 loop, a ten-
residue insertion compared to caspase 1 that
defines the S4 subsite specificity of caspase
3. The sidechain residues of caspase 3
residues Phe381d, Asp381e and Phe381f are
shown in ball-and-stick representation. There is
no indication of any steric clashes between
caspase 1 and CrmA. However, the 381 loop
of caspase 3 would overlap with Phe227 at
the end of s1B in the CrmA molecule, causing
unfavorable interactions and explaining the
weak inhibition of caspase 3 by CrmA.
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Madison and his colleagues [31] identified the signi
ficance of secondary interaction sites, distant from the
substratebinding cleft, in the inhibition of proteases by
serpins. To identify additional interaction sites we gener-
ated a docking model between CrmA and caspases 1 and
3. The structure of CrmA described in this paper is that of
a relaxed, non-inhibitory serpin, but several structures of
uncleaved serpins are available. The RSL in these differ-
ent structures adopts various conformations, suggesting
that this region is highly flexible. There is an ongoing dis-
cussion about which structure is the closest model of the
‘docking’ conformation — the conformation adopted by
serpins in the initial complex. It seems reasonable to
assume, however, that the structure of intact α1-pro-
teinase inhibitor (PDB code 1PSI) might show this
docking conformation, as residues P3–P1 (Ile356, Pro357
and Met358) adopt a substrate-like conformation with
Met358 pointing away from the molecular surface. We
therefore modeled the RSL of intact α1-proteinase
inhibitor onto the structure of cleavage CrmA and super-
imposed this model with caspase 1 (1ICE) or caspase 3
(1PAU). The putative RSL was superimposed with the
tetrapeptide aldehyde inhibitor (Ac-Tyr-Val-Ala-Asp-
CHO) bound to capase 1 or the equivalent Asp-Glu-Val-
Asp inhibitor bound to caspase 3. The resulting models
are shown in Figure 5. This modeling predicts no unfavor-
able interactions between caspase 1 and the putative
docking form of CrmA. CrmA is also a good inhibitor of
caspase 8 [4], and visual inspection of the caspase 8 struc-
tures [32,33] predicts no unfavorable interactions. On the
other hand, docking to caspase 3 leads to severe clashes
between the 381 loop of caspase 3 [34] and residues
around Phe227 (strand s1B) and Phe283 (turn thHs2C) on
the surface of CrmA. The caspase 3 coordinates do not
indicate a high mobility of this loop, although the B factors
in this exposed region are higher than in the core of the
molecule. Therefore, in developing the 381 loop presum-
ably as a requirement for substrate specificity, caspase-3
has also eliminated the possibility of physiological inhibi-
tion by CrmA. Interestingly, CrmA and the CrmA P4–P2
mutant are both extremely weak inhibitors of caspase 7,
the other executioner caspase. Although the structure of
caspase 7 has not been determined, it is predicted to share
with caspase 3 a similar extended 381 loop and compara-
ble extended substrate specificity. Consequently, inhibi-
tion of caspases 3 and 7 (the execution phase of apoptosis)
by a serpin would require a much more extended RSL
than is seen in any of the known structures. Interestingly,
p35 the caspase inhibitor from baculovirus, although not a
serpin, does have such an extended RSL [35] and inhibits
caspases 1, 3 and 8 equally well [36].
Biological implications
Orthopox viruses, including smallpox and cowpox virus,
are among the deadliest mammalian pathogens. Part of
their virulence is due to the large number of proteins
that are apparently used to defeat the host’s response to
viral infection; these proteins are encoded by the ‘host-
range’ genes. The serpin CrmA is an important host-
range gene product that is necessary for the survival of
viral-infected cells, where it blocks the release of pro-
inflammatory mediators and prevents apoptosis of
infected cells. Significantly, CrmA does not block the
execution phase of apoptosis that is mediated by cas-
pases 3 and 7, but only blocks the initiation phase medi-
ated by caspase 8 (and possibly caspase 10).
CrmA lacks regulatory regions found in other serpins
and the conserved Gly344 residue is replaced by a tyro-
sine. Despite these changes, the structure of cleaved
CrmA is nearly identical to that of other cleaved serpins.
The fact that CrmA tolerates a tyrosine at position 344
suggests that the central β sheet A is more flexible than
that found in other serpins and is readily able to accom-
modate the insertion of the bulkier tyrosine residue. One
possibility is that the loss of the D helix in CrmA is
responsible for this increase in flexibility, as this helix is
positioned so as to hinder strand separation and is the
principal site of regulation in other serpins.
Modeling the CrmA structure onto homologous serpins
indicates that severe steric clashes with a loop on
caspase 3 would prevent significant inhibition, and that
it might not be possible to evolve an inhibitor of the exe-
cutioner caspases based on the serpin frame. Indeed, it
may not have been necessary for orthopox viruses to
evolve an inhibitor of the execution phase, since block-
ing the initiation phase would be the most economic
strategy.
Materials and methods
CrmA expression and purification
The expression in E. coli of a C-terminal His6-tagged CrmA (Genbank
accession number P07385) has been described elsewhere [10]. To
obtain a CrmA construct lacking the His6 tag, the coding sequence from
the pFLAG-1 construct including a stop codon, was subcloned into
pET21d (Novagen) using Nco I/Xho I cleavage sites. This construct was
expressed in E. coli strain BL21(DE3)pLysS. Cells were collected after a
6 h induction at 30°C with 0.3 mM isopropyl-β-D-thiogalactopyranoside
(IPTG), resuspended in 100 mM NaCl, 50 mM Tris pH 8, lysed by
freeze/thaw and by sonication, and centrifuged. The lysate of a 1.5 l
culture was diluted into 500 ml buffer containing 20 mM NaCl, 10 mM
Tris, pH 8 and 1 mM dithiothreitol (DTT) and loaded on a 10 ml DEAE-
Sepharose (Sigma) column. CrmA eluted between 200 and 300 mM
NaCl, 20 mM Tris pH 8. These fractions were pooled, dialyzed against
20 mM NaCl, 10 mM Tris (pH8), 1 mM DTT and loaded onto a 1 ml Mono
Q column (Pharmacia). CrmA eluted between 240 and 290 mM NaCl.
Virgin CrmA was cleaved at 37°C for 30 min by subtilisin Carlsberg
(purchased from Sigma, P5380) in 100 mM NaCl, 50 mM Tris pH 8,
10 mM DTT, 1 mM CaCl2 using a 200:1 molar ratio of CrmA:subtilisin.
The reaction was stopped by adding phenylmethane sulphonyl fluoride
(100 times molar excess based on subtilisin concentration). The reac-
tion mixture was re-purified on a Mono Q column.
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Protein crystallization and structure analysis
Crystals were grown using the sitting-drop vapor diffusion method at
protein concentrations of 7–10 mg/ml at 4°C and 23°C. First crystals
grew within two weeks at 4°C by mixing 1 µl protein with 0.7 µl reser-
voir solution (0.1 M Na acetate pH 5, 20% PEG 4000). Crystals of suf-
ficient quality for X-ray diffraction experiments and structure refinement
were obtained at two different conditions: 0.2–0.3 M Na phosphate,
20% PEG 4000 (4°C); and 0.1 M Na acetate pH 5–6, 15% PEG
4000, 0.1 M MgCl2 (23°C). They grew between one week and several
months and belonged to the space groups C2221 and P212121 (see
Table 1). Data were collected on an R-AXIS IV image plate mounted on
a Rigaku rotating anode (C2221) and at the X-25 beamline in
Brookhaven (P212121). Data were processed and scaled in
DENZO/SCALEPACK [37].
The data set from the C2221 crystal form was the first available. The
structure was solved using Patterson techniques with the program
AMoRe [38] (integration radius 30 Å, resolution range 10–4 Å) and the
structure of cleaved horse leukocyte elastase inhibitor (1HLE) as search
model. Both rotational and translational searches gave clear peaks (12.5
sigma versus 6.6 and 27.0 sigma versus 23.7); after rigid-body refine-
ment the correlation factor was 28.7%. Map interpretation has been
done in MAIN [39], crystallographic refinement (simulated annealing,
positional and temperature-factor refinement) in CNS [40] using the
parameters of Engh and Huber [41]. Although almost all residues,
except for residues of the D helix and some terminal residues, could be
fitted into the electron density, the R factor did not drop below 30%
(Rfree 35.5%). Data analysis as described by Yeates [42] indicated
merohedral twinning as a reason for the problems with data refinement.
The degree of twinning was estimated to be between 20% to 30%. The
twinning is a result of a 180° rotation along the diagonal of the ac plane.
In the space group C2221 this is only possible if the axis a and c are of
equal length. However, crystallographic refinement in SHELX [43], a
program that allows the refinement of the twining factor α as an inde-
pendent parameter, did not improve the R factor or the electron density.
The structure was finished after the data set from P212121 became avail-
able. An unfinished CrmA structure from the C2221 data set was used
to locate the molecule in the P212121 packing. The Patterson search
was done in AMoRe and gave a clear solution with a correlation factor of
58.9%. With this data the structure could be refined to an R factor of
23.3% (a summary of the refinement statistics is given in Table 1). In the
final model 329 out of 341 residues are defined by electron density.
Inhibition kinetics
Recombinant caspases were purified and characterized as previ-
ously described [44], and inhibition by CrmA and CrmA mutants was
followed by the method of progress curves in reactions containing at
least a tenfold molar excess of inhibitor [4], using carbobenzoxy-Asp-
Glu-Val-Asp-7-amino-4-trifluoromethyl coumarin as reporter sub-
strate. Apparent inhibition rate constants were determined during the
approach to steady state of substrate hydrolysis, and were deter-
mined by the method of progress curves, where a reaction was initi-
ated by the addition of enzyme to a mixture of substrate and inhibitor.
The inhibitor concentration was kept at a large excess of enzyme to
render the reaction pseudo-first order for convenience of analysis.
Calculations of kinetic parameters are based on a single-step reac-
tion scheme [4]. 
The first order rate constant (kobs) was derived from: 
In([P]t + ∆t – [P]t) = C – kobst (1)
where [P] t + ∆t is the product concentration at time t + ∆t of the associ-
ation reaction and [P]t is the product concentration at time t [45]. The
second order rate constant (ka) was derived according to the follow-
ing relationship: 
ka = (kobs/I)(1 = S/Km) (2)
where S is the concentration of substrate and Km is the Michaelis
constant.
Accession numbers
The coordinates of CrmA in its cleaved form have been deposited in
the Protein Data Bank with accession code 1F0C.
Acknowledgements
We thank Annamarie Price for help with expressing proteins, José de
Pereda, Chao-Zhou Ni and Karl-Peter Hopfner for their input in data pro-
cessing and structure refinement, and Ed Madison for comments on the
manuscript. This work was supported by National Institutes of Health grant
HL51399 to GSS, and a fellowship from the Deutschen Akademischen
Austauschdienst to MR.
References
1. Salvesen, G.S. & Dixit, V.M. (1997). Caspases: intracellular signaling
by proteolysis. Cell 91, 443-446.
2. Thornberry, N.A. & Lazebnik, Y. (1998). Caspases: enemies within.
Science 281, 1312-1306.
3. Ray, C.A., et al., & Pickup, D.J. (1992). Viral inhibition of inflammation:
cowpox virus encodes an inhibitor of the interleukin-1β-converting
enzyme. Cell 69, 597-604.
4. Zhou, Q., Snipas, S., Orth, K., Dixit, V.M. & Salvesen, G.S. (1997).
Target protease specififity of the viral serpin CrmA: analysis of five
caspases. J. Biol. Chem. 273, 7797-7800.
5. Walsh, C.M., Wen, B.G., Chinnaiyan, A.M., O’Rourke, K., Dixit, V.M. 
& Hedrick, S.M. (1998). A role for FADD in T cell activation and
development. Immunity 8, 439-449.
6. Komiyama, T., et al., & Salvesen, G. (1994). Inhibition of interleukin-
1beta converting enzyme by the cowpox virus serpin CrmA. An
example of cross-class inhibition. J. Biol. Chem. 269, 19331-19337.
7. Turner, S., Kenshole, B. & Ruby, J. (1999). Viral modulation of the host
response via crmA/SPI-2 expression. Immunol. Cell Biol.
77, 236-241.
8. Pickup, D.J., Ink, B.S., Hu, W., Ray, C.A. & Joklik, W.K. (1986).
Hemorrhage in lesions caused by cowpox virus is induced by a viral
protein that is related to plasma protein inhibitors of serine proteases.
Proc. Natl Acad. Sci. USA 83, 7698-7702.
9. Potempa, J., Korzus, E. & Travis, J. (1994). The serpin superfamily of
proteinase inhibitors: structure, function, and regulation. J. Biol.
Chem. 269, 15957-15960.
10. Quan, L.T., Caputo, A., Bleackley, R.C., Pickup, D.J. & Salvesen, G.S.
(1995). Granzyme B is inhibited by the cowpox virus serpin CrmA. 
J. Biol. Chem. 270, 10377-10379.
11. Komiyama, T., Quan, L.T. & Salvesen, G.S. (1996). Inhibition of
cysteine and serine proteinases by the cowpox virus serpin CrmA.
Adv. Exp. Med. Biol. 389, 173-176.
12. Bode, W. & Huber, R. (1992). Natural protein proteinase inhibitors
and their interaction with proteinases. Eur. J. Biochem. 204, 433-451.
13. Marshall, C.J. (1993). Evolutionary relationships among the serpins.
Phil. Trans. R. Soc. Lond. B 342, 101-119.
14. Huber, R. & Carrell, R.W. (1989). Implications of the three-
dimensional structure of α1-antitrypsin for structure and function of
serpins. Biochemistry 28, 8966-8971.
15. Loebermann, H., Tokuoka, R., Deisenhofer, J. & Huber, R. (1984).
Human α1-proteinase inhibitor: crystal structure analysis of two
modifications, molecular model and preliminary analysis of the
implications for function. J. Mol. Biol. 177, 531-556.
16. Baumann, U., Huber, R., Bode, W., Grosse, D., Lesjak, M. & Laurell,
C.B. (1991). Crystal structure of cleaved human α1-antichymotrypsin
at 2.7 Å resolution and its comparison with other serpins. J. Mol. Biol.
218, 595-606.
17. Schreuder, H., et al., & Theunissen, H. (1993). Crystallization and
preliminary X-ray analysis of human antithrombin III. J. Mol. Biol.
229, 249-250.
18. Mourey, L., Samama, J.P., Delarue, M., Petitou, M., Choay, J. & Moras,
D. (1993). Crystal structure of cleaved bovine antithrombin III at 3.2 Å
resolution. J. Mol. Biol. 232, 223-241.
19. Baumann, U., Bode, W., Huber, R., Travis, J. & Potempa, J. (1992).
Crystal structure of cleaved equine leucocyte elastase inhibitor
determined at 1.95 Å resolution. J. Mol. Biol. 226, 1207-1218.
20. Carrell, R.W., Stein, P.E., Fermi, G. & Wardell, M.R. (1994).
Biological implications of 3 Å structure of dimeric antithrombin.
Structure 2, 257-270.
796 Structure 2000, Vol 8 No 7
st8711.qxd  07/03/2000  09:43  Page 796
21. Whinna, H.C., Blinder, M.A., Szewczyk, M., Tollefsen, D.M. & Church,
F.C. (1991). Role of lysine 173 in heparin binding to heparin cofactor
II. J. Biol. Chem. 266, 8129-8135.
22. Dickinson, J.L., Norris, B.J., Jensen, P.H. & Antalis, T.M. (1998). The C-
D interhelical domain of the serpin plasminogen activator inhibitor-type
2 is required for protection from TNF-alpha induced apoptosis. Cell
Death Differ. 5, 163-171.
23. Chuang, T.L. & Schleef, R.R. (1999). Identification of a nuclear
targeting domain in the insertion between helices C and D in protease
inhibitor-10. J. Biol. Chem. 274, 11194-11198.
24. Gettins, P., Patston, P.A. & Schapira, M. (1993). The role of
conformational changes in serpin structure and function. BioEssays
15, 461-467.
25. Wright, H.T. & Scarsdale, J.N. (1995). Structural basis for serpin
inhibitor activity. Proteins 22, 210-225.
26. Elliott, P.R., Lomas, D.A., Carrell, R.W. & Abrahams, J.P. (1996).
Inhibitory conformation of the reactive loop of alpha 1-antitrypsin. 
Nat. Struct. Biol. 3, 676-681.
27. Schulze, A.J., Frohnert, P.W., Engh, R.A. & Huber, R. (1992). Evidence
for the extent of insertion of the active site loop of intact α1-proteinase
inhibitor in β-sheet A. Biochemistry 31, 7560-7565.
28. Hood, D.B., Huntington, J.A. & Gettins, P.G.W. (1994). α1-Proteinase
inhibitor variant T345R. Influence of P14 residue on substrate and
inhibitory pathways. Biochemistry 33, 8538-8547.
29. Thornberry, N.A., et al., & Nicholson, D.W. (1997). A combinatorial
approach defines specificities of members of the caspase family and
granzyme B. J. Biol. Chem. 272, 17907-17911.
30. Ekert, P.G., Silke, J. & Vaux, D.L. (1999). Inhibition of apoptosis and
clonogenic survival of cells expressing crmA variants: optimal caspase
substrates are not necessarily optimal inhibitors. EMBO J.
18, 330-338.
31. Madison, E.L., Goldsmith, E.J., Gerard, R.D., Gething, M.J. &
Sambrook, J.F. (1989). Serpin-resistant mutants of human tissue-type
plasminogen activator. Nature 339, 721-724.
32. Blanchard H., et al., & Grutter M.G. (1999). The three-dimensional
structure of caspase-8: an initiator enzyme in apoptosis. Structure
7, 1125-1133.
33. Watt W., Koeplinger K.A., Mildner A.M., Heinrikson R.L., Tomasselli
A.G. & Watenpaugh K.D. (1999). The atomic-resolution structure of
human caspase-8, a key activator of apoptosis. Structure 
7, 1135-1143.
34. Rotonda, J., et al., & Becher, J.W. (1996). The three-dimensional
structure of apopain/CPP32, a key mediator of apoptosis. Nat. Struct.
Biol. 3, 619-625.
35. Fisher, A.J., Cruz, W., Zoog, S.J., Schneider, C.L. & Friesen, P.D.
(1999). Crystal structure of baculovirus P35: role of a novel reactive-
site loop in apoptotic caspase inhibition. EMBO J. 18, 2031-2039.
36. Zhou, Q., et al., & Salvesen, G.S. (1998). Interaction of the
baculovirus anti-apoptotic protein p35 with caspases: specificity,
kinetics, and characterization of the caspase/p35 complex.
Biochemistry 37, 10757-10765.
37. Otwinowski, Z. & Minor, W. (1997). Processing of X-ray diffraction
data collected in oscillation mode. Methods Enzymol. 276, 307-326.
38. Navazza, J. (1994). AMoRe: an automated package for molecular
replacement. Acta Crystallogr. A 50, 157-163.
39. Turk D. (1992). Weiterentwicklung eines Programmes für
Molekülgraphik und Elektronendichte-Manipulation und seine
Anwendung auf verschiedene Protein-Strukturaufklärungen. PhD
Thesis, Technische Universität, München, Germany.
40. Brünger, A.T., et al., & Warren, G.L. (1998). Crystallography & NMR
system (CNS): a new software suite for macromolecular structure
determination. Acta Crystallogr. D 54, 905-921.
41. Engh, R.A. & Huber, R. (1991). Accurate bond and angle parameters
for X-ray protein-structure refinement. Acta Crystallogr. A 
47, 392-400.
42. Yeates, T.O. (1997). Detecting and overcoming crystal twinning.
Methods Enzymol. 276, 344-358.
43. Sheldrick, G.M. & Schneider, T.R. (1997). SHELXL: high resolution
refinement. Methods Enzymol. 277, 319-343.
44. Stennicke, H.R. & Salvesen, G.S. (1999). Caspases: preparation and
characterization. Methods 17, 313-319.
45. Knight, C.G. (1986). The characterization of enzyme inhibition. In
Proteinase Inhibitors. (Barrett, A.J. & Salvesen, G. eds) pp. 23-51,
Elsevier Science Publishers BV, Amsterdam. 
46. Kraulis, P. J. (1991). MOLSCRIPT: a program to produce both
detailed and schematic plots of protein structures. J. Appl. Cryst.
24, 946-950.
47. Merritt, E.A. & Murphy, M.E.P. (1994). Raster3D Version 2.0 — a
program for photorealistic molecular graphics. Acta Crystallogr. 
D 50, 869-873.
48. Barton, G.J. (1993). ALSCRIPT: a tool to format multiple sequence
alignments. Protein Eng. 6, 37-40.
49. Esnouf, R.M. (1997). An extensively modified version of MolScript that
includes greatly enhances coloring capabilities. J. Mol. Graph.
15, 132-134.
Research Article  Structure of cleaved CrmA Renatus et al. 797
Because Structure with Folding & Design operates a
‘Continuous Publication System’ for Research Papers, this
paper has been published on the internet before being printed
(accessed from http://biomednet.com/cbiology/str). For
further information, see the explanation on the contents page.
st8711.qxd  07/03/2000  09:43  Page 797
